摘要:
A composition includes a salt of a carboxyethyl phosphinate ester compound. Additionally, the composition may also include a polymeric resin, such as a thermoplastic resin. The composition may have improved physical and chemical properties including flame retardancy, thermal stability, and hygroscopicity.
摘要:
A polymer composition includes a polymer resin and a carboxylate phosphinate salt compound. The polymer composition can include a thermoplastic resin and a carboxylate phosphinate salt compound. A molded article and electronic devices can be made from the polymer composition.
摘要:
A flame retardant molding composition includes a rubber modified aromatic vinyl resin, a polyphenylene ether resin, and a cyclic phosphonate ester compound. A shaped article and an electronic device can be made from the flame retardant molding composition.
摘要:
This invention relates to the oral pharmaceutical composition of metformin and rosuvastatin. In detail, this invention comprising metformin, rosuvastatin, sustained release carriers and/or excipients reduces the side effects caused by statins and enhances safety, patients' convenience and compliance with its one-per-day dosage. In addition, regulation of an early effective blood concentration of the drug and maintenance of the drug's concentration at a steady level in vivo by a controlled-release can be advantageously used as a pharmaceutical composition for preventing and treating hyperlipidemia.
摘要:
Provided is a sustained-release formulation: (a) a sustained-release core including an active ingredient and a polymer having erosion and swelling property in mammalian intestinal secretions, (b) an enteric film coating layer coated on the sustained-release core, and (c) an active ingredient-containing film coating layer coated on the enteric film coating layer and including the active ingredient and hydrophilic polymer for film coating.
摘要:
Disclosed is a stable pharmaceutical solution preparation of erythropoietin (EPO), which includes a stabilizing agent not containing a blood-derived protein, thereby maintaining EPO activity for a prolonged period of time without the risk of viral contamination. The stable solution preparation further includes a non-ionic surfactant and a tonicity agent, thereby preventing EPO loss during storage and facilitating administration to the body.
摘要:
Provided is a method of preparing low-crystallinity oltipraz or amorphous oltipraz. The method includes: obtaining a mixed solution containing oltipraz and a water-soluble polymer or a water-insoluble polymer in a solvent, the solvent being an organic solvent or purified water; and solid-dispersing the oltipraz in the polymer. In the solid-dispersing, the mixed solution may be spray dried using a spray dryer or granulated using a fluid bed granulator.